Filtered By:
Cancer: Hepatocellular Carcinoma
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 52 results found since Jan 2013.
Loco-regional treatment of hepatocellular carcinoma: Role of contrast-enhanced ultrasonography
World J Hepatol. 2022 May 27;14(5):911-922. doi: 10.4254/wjh.v14.i5.911. Epub 2022 Apr 7.ABSTRACTHepatocellular carcinoma (HCC) is one of the few cancers for which locoregional treatments (LRTs) are included in international guidelines and are considered as a valid alternative to conventional surgery. According to Barcelona Clinic Liver Cancer classification, percutaneous treatments such as percutaneous ethanol injection, radiofrequency ablation and microwave ablation are the therapy of choice among curative treatments in patients categorized as very early and early stage, while transcatheter arterial chemoembolization is ...
Source: World Journal of Hepatology - June 20, 2022 Category: Gastroenterology Authors: Agostino Inzerillo Maria Franca Meloni Adele Taibbi Tommaso Vincenzo Bartolotta Source Type: research
CCL24 Signaling in the Tumor Microenvironment
Adv Exp Med Biol. 2021;1302:91-98. doi: 10.1007/978-3-030-62658-7_7.ABSTRACTChemokines with their network play an important role in cancer growth, metastasis, and host-tumor interactions. Of many chemokines, C-C motif chemokine ligand 24 (CCL24) has been shown to contribute to tumorigenesis as well as inflammatory diseases like asthma, allergies, and eosinophilic esophagitis. CCL24 is expressed in some tumor cells such as colon cancer, hepatocellular carcinoma, and cutaneous T cell lymphoma. CCL24 can be used as a potential biomarker in several cancers including colon cancer, non-small cell cancer, and nasopharyngeal carci...
Source: Advances in Experimental Medicine and Biology - July 21, 2021 Category: Research Authors: Sung-Jig Lim Source Type: research
Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
CONCLUSION: Greater frequency and higher grades of irAEs are associated with better treatment response in patients with RCC and urothelial malignancy receiving ICI therapy. The presence of liver metastases denotes a negative predictive marker for immunotherapy efficacy.
SUMMARY: Immune checkpoint inhibitors (ICI) are increasingly used to treat genitourinary (GU) malignancies. However, clinical data regarding patients with advanced-stage GU malignancies treated with ICI is lacking. Thus, we performed a single-center, retrospective cohort study on patients with metastatic and unresectable renal cell carcinoma (RCC) and ...
Source: Urologic Oncology - January 22, 2021 Category: Urology & Nephrology Authors: Ma VT, Su CT, Hu M, Taylor JMG, Daignault-Newton S, Kellezi O, Dahl MN, Shah MA, Erickson S, Lora J, Hamasha R, Ali A, Yancey S, Kiros L, Balicki HM, Winfield DC, Green MD, Alva AS Tags: Urol Oncol Source Type: research
